VCM
ELVN icon

Versant Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Versant Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Buy
1,581
+6
+0.4% +$255 0.01% 1052
2026
Q1 		$61.7K Buy
1,575
+1,363
+643% +$37.8K 0.01% 1108
2025
Q4 		$3.27K Sell
212
-333
-61% -$6.63K ﹤0.01% 2364
2025
Q3 		$11.2K Buy
545
+266
+95% +$5.36K ﹤0.01% 1886
2025
Q2 		$5.6K Buy
279
+212
+316% +$4.01K ﹤0.01% 2113
2025
Q1 		$1.32K Hold
67
– – ﹤0.01% 2321
2024
Q4 		$1.51K Hold
67
– – ﹤0.01% 2113
2024
Q3 		$1.71K Buy
+67
New +$1.55K ﹤0.01% 1610

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Versant Capital Management's ELVN Position: Q2 2026 in Review

Versant Capital Management increased its Enliven Therapeutics (ELVN) stake by 0.38% in Q2 2026, buying an estimated $255 and bringing the position to 1,581 shares worth $80.2K. The position accounts for 0.01% of the portfolio, ranked #1052.

Versant Capital Management first reported a position in ELVN in Q3 2024 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Versant Capital Management held 1,581 shares of Enliven Therapeutics worth $80.2K as of Q2 2026.
  • Versant Capital Management bought 6 Enliven Therapeutics shares in Q2 2026, an estimated $255.
  • Enliven Therapeutics made up 0.01% of Versant Capital Management's portfolio in Q2 2026, its #1052 holding.
  • Versant Capital Management first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.